应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
CDE 科尔黛伦矿业
已收盘 03-28 16:00:00 EDT
6.09
-0.25
-3.94%
盘后
6.12
+0.03
+0.49%
19:58 EDT
最高
6.53
最低
6.04
成交量
1,957万
今开
6.38
昨收
6.34
日振幅
7.73%
总市值
38.89亿
流通市值
38.50亿
总股本
6.39亿
成交额
1.21亿
换手率
3.10%
流通股本
6.32亿
市净率
3.46
ROE
5.49%
每股收益
0.15
52周最高
7.72
52周最低
3.60
市盈率
40.60
股息
0.00
股息收益率
0.00
ROA
5.24%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
美诺华(603538.SH)子公司沙库巴曲缬沙坦钠原料药通过CDE技术审评
智通财经 · 03-07
美诺华(603538.SH)子公司沙库巴曲缬沙坦钠原料药通过CDE技术审评
亚盛医药-B早盘涨超5% 耐立克®第三次获CDE纳入突破性治疗品种
新浪港股 · 03-07
亚盛医药-B早盘涨超5% 耐立克®第三次获CDE纳入突破性治疗品种
港股异动 | 亚盛医药-B(06855)盘中涨超4% 耐立克®第三次获CDE纳入突破性治疗品种
智通财经 · 03-07
港股异动 | 亚盛医药-B(06855)盘中涨超4% 耐立克®第三次获CDE纳入突破性治疗品种
和誉-B：新型PRMT5*MTA抑制剂ABSK131的IND申请获中国CDE批准
新浪港股 · 03-07
和誉-B：新型PRMT5*MTA抑制剂ABSK131的IND申请获中国CDE批准
和誉-B(02256)：新型PRMT5*MTA抑制剂 ABSK131的IND申请获中国CDE批准
智通财经 · 03-06
和誉-B(02256)：新型PRMT5*MTA抑制剂 ABSK131的IND申请获中国CDE批准
科尔黛伦矿业盘中异动 股价大涨5.13%
市场透视 · 03-05
科尔黛伦矿业盘中异动 股价大涨5.13%
金十数据整理：每日美股市场要闻速递（3月4日 周二）
美港电讯 · 03-04
金十数据整理：每日美股市场要闻速递（3月4日 周二）
美国药企3.5亿美元预付款引进一款减重药，新靶点胰淀素潜力多大？
澎湃新闻 · 03-04
美国药企3.5亿美元预付款引进一款减重药，新靶点胰淀素潜力多大？
默沙东(MRK.US)来特莫韦微片拟纳入CDE优先审评 属儿童新品种
智通财经 · 03-04
默沙东(MRK.US)来特莫韦微片拟纳入CDE优先审评 属儿童新品种
异动解读 | 科尔黛伦矿业盘中大涨5.11%,有望凭借良好业绩和机构看好行情持续上涨
异动解读 · 02-26
异动解读 | 科尔黛伦矿业盘中大涨5.11%,有望凭借良好业绩和机构看好行情持续上涨
天宇股份(300702.SZ)：甲苯磺酸艾多沙班原料药通过CDE审评
智通财经 · 02-24
天宇股份(300702.SZ)：甲苯磺酸艾多沙班原料药通过CDE审评
天宇股份：全资子公司原料药通过CDE审评
美港电讯 · 02-24
天宇股份：全资子公司原料药通过CDE审评
信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评
美通社 · 02-23
信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评
【信达生物(01801.HK)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评】信达生物(01801.HK)公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。
金融界 · 02-23
【信达生物(01801.HK)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评】信达生物(01801.HK)公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。
科尔黛伦矿业2024财年实现净利润58.90百万美元，同比增加156.63%
市场透视 · 02-22
科尔黛伦矿业2024财年实现净利润58.90百万美元，同比增加156.63%
Roth MKM：维持Coeur Mining(CDE.US)评级，由买入调整至买入评级, 目标价由8.50美元调整至8.25美元。
金融界 · 02-21
Roth MKM：维持Coeur Mining(CDE.US)评级，由买入调整至买入评级, 目标价由8.50美元调整至8.25美元。
Coeur Mining 2024年第四季度调整后每股收益为0.18美元，超过预期的0.14美元，销售额为3.05亿美元，不及预期的3.1432亿美元
财报速递 · 02-19
Coeur Mining 2024年第四季度调整后每股收益为0.18美元，超过预期的0.14美元，销售额为3.05亿美元，不及预期的3.1432亿美元
加拿大蒙特利尔银行：重申Coeur Mining(CDE.US)优于大市评级, 目标价9.00美元。
金融界 · 02-18
加拿大蒙特利尔银行：重申Coeur Mining(CDE.US)优于大市评级, 目标价9.00美元。
多家国产药企布局“流感神药”、最早年内上市，罗氏速福达前景堪忧
蓝鲸财经 · 02-18
多家国产药企布局“流感神药”、最早年内上市，罗氏速福达前景堪忧
诺诚健华(688428.SH)：BCL2抑制剂ICP-248联合奥布替尼治疗一线CLL/SLL的注册性Ⅲ期临床试验获CDE批准
智通财经 · 02-17
诺诚健华(688428.SH)：BCL2抑制剂ICP-248联合奥布替尼治疗一线CLL/SLL的注册性Ⅲ期临床试验获CDE批准
加载更多
公司概况
公司名称：
科尔黛伦矿业
所属市场：
NYSE
上市日期：
1986-12-01
主营业务：
Coeur Mining, Inc.是一家主要的白银生产商，目前其黄金生产也不断加大。该公司在美国，墨西哥，玻利维亚，阿根廷和澳大利亚都有其资产。该公司于2010年8月售出其在智利的Cerro Bayo矿产。Coeur矿业公司于1928年在爱达荷州注册成立。该公司的业务策略是发现，获取，开发和运营低成本金银的业务。该业务将产生长期的现金流，并通过不断的探索提供增长机会，为股东带来卓越和持续的回报。
发行价格：
--
{"stockData":{"symbol":"CDE","market":"US","secType":"STK","nameCN":"科尔黛伦矿业","latestPrice":6.09,"timestamp":1743192000000,"preClose":6.34,"halted":0,"volume":19572418,"hourTrading":{"tag":"盘后","latestPrice":6.1201,"preClose":6.09,"latestTime":"19:58 EDT","volume":174498,"amount":1062999.1859,"timestamp":1743206335065},"delay":0,"floatShares":632242850,"shares":638557875,"eps":0.15,"marketStatus":"已收盘","change":-0.25,"latestTime":"03-28 16:00:00 EDT","open":6.38,"high":6.53,"low":6.04,"amount":121445162.6330848,"amplitude":0.077287,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.15,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":533797200000,"exchange":"NYSE","adjPreClose":6.34,"preHourTrading":{"tag":"盘前","latestPrice":6.43,"preClose":6.34,"latestTime":"09:29 EDT","volume":162690,"amount":1043748.3511949999,"timestamp":1743168599452},"postHourTrading":{"tag":"盘后","latestPrice":6.1201,"preClose":6.09,"latestTime":"19:58 EDT","volume":174498,"amount":1062999.1859,"timestamp":1743206335065},"volumeRatio":1.049922,"impliedVol":1.1114,"impliedVolPercentile":0.936},"requestUrl":"/m/hq/s/CDE","defaultTab":"news","newsList":[{"id":"2517174850","title":"美诺华(603538.SH)子公司沙库巴曲缬沙坦钠原料药通过CDE技术审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2517174850","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517174850?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:08","pubTimestamp":1741334904,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美诺华(603538.SH)发布公告，近日，公司全资子公司宣城美诺华药业有限公司(简称“宣城美诺华”)收到国家药品监督管理局(核准签发的沙库巴曲缬沙坦钠原料药《化学原料药上市申请批准通知书》，该药品适应症：用于治疗原发性高血压。宣城美诺华的沙库巴曲缬沙坦钠原料药通过CDE技术审评，证明该原料药已符合国家相关药品审评技术标准，可销售至国内市场，将进一步丰富子公司的产品线，有助于拓展公司业务领域，有利于进一步扩展公司原料药制剂一体化生产范围，增强公司一体化生产的优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603538","BK0239","CDE","BK4017"],"gpt_icon":0},{"id":"2517147943","title":"亚盛医药-B早盘涨超5% 耐立克®第三次获CDE纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2517147943","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517147943?lang=zh_cn&edition=full","pubTime":"2025-03-07 10:47","pubTimestamp":1741315620,"startTime":"0","endTime":"0","summary":" 亚盛医药-B早盘上涨5.07%，现报40.45港元，成交额7852.04万港元。 亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性（Ph+）急性淋巴细胞白血病患者。 据悉，这是耐立克第三次获CDE纳入突破性治疗品种。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-07/doc-inenuuym7106212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CDE","BK4139","06855","BK4017","BK1574","AAPG","BK1161"],"gpt_icon":0},{"id":"2517903144","title":"港股异动 | 亚盛医药-B(06855)盘中涨超4% 耐立克®第三次获CDE纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903144","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517903144?lang=zh_cn&edition=full","pubTime":"2025-03-07 10:21","pubTimestamp":1741314098,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B盘中涨超4%，截至发稿，涨4.55%，报40.25港元，成交额5269.94万港元。消息面上，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者。据悉，这是耐立克第三次获CDE纳入突破性治疗品种。耐立克是亚盛医药原创1类新药，为中国首个获批上市的第三代BCR-ABL抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06855","CDE","BK4017","BK1574","AAPG","BK4139"],"gpt_icon":0},{"id":"2517110880","title":"和誉-B：新型PRMT5*MTA抑制剂ABSK131的IND申请获中国CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517110880","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517110880?lang=zh_cn&edition=full","pubTime":"2025-03-07 08:14","pubTimestamp":1741306440,"startTime":"0","endTime":"0","summary":" 和誉-B发布公告，2025年3月6日，上海和誉生物医药科技有限公司今日宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131的临床研究申请已获中国国家药品监督管理局药品审评中心批准。2024年12月初，其IND申请已获美国FDA 批准。 将在晚期实体瘤患者中开展一项I期临床研究，名为“一项评估ABSK131在晚期╱ 转移性实体瘤患者中的安全性、耐受性、药代动力学和初步有效性的I期、首次人体、多中心、开放性研究”。 约15%的实体瘤缺乏抑癌基因MTAP的表达。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-07/doc-inenuqsv0155229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MTA","LU2488822045.USD","CDE","02256","BK4017","BK4188","BK1161"],"gpt_icon":0},{"id":"2517508901","title":"和誉-B(02256)：新型PRMT5*MTA抑制剂 ABSK131的IND申请获中国CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517508901","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517508901?lang=zh_cn&edition=full","pubTime":"2025-03-06 21:45","pubTimestamp":1741268747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，2025年3月6日，上海和誉生物医药科技有限公司今日宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131的临床研究申请已获中国国家药品监督管理局药品审评中心批准。2024年12月初，其IND申请已获美国FDA 批准。约15%的实体瘤缺乏抑癌基因MTAP的表达。PRMT5 在MTAP缺失肿瘤中表现出“合成致死”效应。近期研究显示，选择性靶向抑制PRMT5*MTA有望成为MTAP缺失肿瘤的新型治疗策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4188","BK1161","MTA","02256","BK4017","CDE","LU2488822045.USD"],"gpt_icon":0},{"id":"2517294666","title":"科尔黛伦矿业盘中异动 股价大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517294666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517294666?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:07","pubTimestamp":1741187272,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时07分，科尔黛伦矿业股票出现异动，股价急速上涨5.13%。截至发稿，该股报5.44美元/股，成交量270.43万股，换手率0.42%，振幅5.90%。科尔黛伦矿业股票所在的黄金行业中，整体涨幅为1.07%。科尔黛伦矿业公司简介：科尔黛伦矿业有限公司 是一家专注于美洲贵金属开采的金属生产商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305230752989d4e7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305230752989d4e7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CDE","BK4017"],"gpt_icon":0},{"id":"2516671650","title":"金十数据整理：每日美股市场要闻速递（3月4日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2516671650","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516671650?lang=zh_cn&edition=full","pubTime":"2025-03-04 21:50","pubTimestamp":1741096236,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1839511570.USD","BK4591","SGXZ31699556.SGD","LU1116320737.USD","BK4552","LU0061475181.USD","LU0265550946.USD","LU2756315664.SGD","LU1868836757.USD","GB00BDT5M118.USD","SE","BK4585","CDE","SG9999014559.SGD","LU2663582299.SGD","SEA","TSLA","SG9999002620.SGD","BK4505","LU0820561909.HKD","LU0823421333.USD","03145","IE0004091025.USD","MRK","IE00BWXC8680.SGD","TSYW.SI","159813","BK4503","LU1868837300.USD","SG9999014542.SGD","LU0516422366.SGD","LU0820561818.USD","LU2125154778.USD","TSM","IE00B19Z3B42.SGD","TSLL","LU1861220033.SGD","BK4533","LU0985320562.USD","LU2458330243.SGD","SG9999018865.SGD","LU0737861269.HKD","UBER","EWT","BK4588","LU1116320901.HKD","TWmain","LU0823414478.USD","SG9999014484.SGD","LU0889566641.SGD"],"gpt_icon":0},{"id":"2516367597","title":"美国药企3.5亿美元预付款引进一款减重药，新靶点胰淀素潜力多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2516367597","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516367597?lang=zh_cn&edition=full","pubTime":"2025-03-04 20:58","pubTimestamp":1741093105,"startTime":"0","endTime":"0","summary":"又有跨国药企进入减重赛道，减肥新靶点再获关注。3月3日，美国生物制药企业艾伯维宣布，与丹麦生物科技公司Gubra达成共同开发GUB014295的许可协议。这款在研产品处于一期临床研究阶段。根据协议条款，艾伯维将在全球范围内主导GUB014295的开发和商业化活动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043336250137.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043336250137.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4017","CDE"],"gpt_icon":0},{"id":"2516756386","title":"默沙东(MRK.US)来特莫韦微片拟纳入CDE优先审评 属儿童新品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2516756386","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516756386?lang=zh_cn&edition=full","pubTime":"2025-03-04 20:47","pubTimestamp":1741092466,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，今日，中国国家药监局药品审评中心官网刚刚公示，默沙东申报的来特莫韦微片拟纳入优先审评，用于接受异基因造血干细胞移植的巨细胞病毒血清学阳性的成人和6个月及以上且体重≥6kg的儿童受者[R+]预防巨细胞病毒感染和巨细胞病毒病。根据CDE公示，来特莫韦微片属于儿童新品种。研究表明，这些患者当中，巨细胞病毒的血清阳性率可高达90%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BBT3K403.USD","BK4534","SG9999001440.SGD","IE000M9KFDE8.USD","LU0208291251.USD","LU0265550946.USD","LU0266013472.USD","BK4550","LU1066051498.USD","LU2468319806.SGD","LU0211331839.USD","LU1057294990.SGD","LU1093756168.USD","LU1116320901.HKD","IE00B4R5TH58.HKD","CDE","LU0203347892.USD","LU2023250843.SGD","SG9999002224.SGD","LU1037948897.HKD","SG9999014575.USD","MRK","LU0122379950.USD","LU0320765489.SGD","LU0965509283.SGD","LU1291159041.SGD","LU1035773651.USD","LU1093756325.SGD","LU0861579265.USD","LU2361044865.SGD","BK4559","SG9999014567.USD","LU2361044949.HKD","LU1974910355.USD","LU0234572021.USD","LU0265550359.USD","LU1066053197.SGD","LU1571399168.USD","BK4007","LU1934455277.USD","BK4516","LU2106854487.HKD","BK4588","LU1066051225.USD","IE00BLSP4239.USD","LU2361045086.USD","BK4585","LU0058720904.USD","LU1162221912.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"1157102228","title":"异动解读 | 科尔黛伦矿业盘中大涨5.11%,有望凭借良好业绩和机构看好行情持续上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1157102228","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157102228?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:24","pubTimestamp":1740587083,"startTime":"0","endTime":"0","summary":"2025年2月26日周三盘中交易时段,科尔黛伦矿业出现大涨行情,股价上涨5.11%,引发市场关注。近期,科尔黛伦矿业发布了最新财报数据,较上年同期表现出色,实现营业收入10.71亿美元,净利润5890万美元,每股收益0.15美元,显示公司基本面良好,财务状况稳健。另一方面,科尔黛伦矿业所处的黄金矿业整体景气向好,整个行业当日涨幅达1.19%。因此,得益于良好的基本面、同业评级看涨以及所在行业向好的态势,科尔黛伦矿业股价在盘中阶段出现了大涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 科尔黛伦矿业盘中大涨5.11%,有望凭借良好业绩和机构看好行情持续上涨","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CDE"],"gpt_icon":0},{"id":"2513613745","title":"天宇股份(300702.SZ)：甲苯磺酸艾多沙班原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2513613745","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513613745?lang=zh_cn&edition=full","pubTime":"2025-02-24 18:04","pubTimestamp":1740391498,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天宇股份(300702.SZ)公告，公司全资子公司浙江京圣药业有限公司(简称“京圣药业”)甲苯磺酸艾多沙班原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。公告显示，甲苯磺酸艾多沙班用于伴有一个或多个风险因素(如充血性心力衰竭、高血压、年龄≥75岁、糖尿病、既往卒中或短暂性脑缺血发作(TIA)病史)的非瓣膜性房颤(NVAF)成人患者，预防卒中和体循环栓塞;用于治疗成人深静脉血栓(DVT)和肺栓塞(PE)，以及预防成人深静脉血栓和肺栓塞复发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4017","BK0239","CDE","300702"],"gpt_icon":0},{"id":"2513358745","title":"天宇股份：全资子公司原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2513358745","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513358745?lang=zh_cn&edition=full","pubTime":"2025-02-24 18:00","pubTimestamp":1740391215,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","BK4017","CDE","300702"],"gpt_icon":0},{"id":"2513976262","title":"信达生物宣布首个中国研发的CTLA-4单抗伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2513976262","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513976262?lang=zh_cn&edition=full","pubTime":"2025-02-24 07:52","pubTimestamp":1740354720,"startTime":"0","endTime":"0","summary":"伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。研究旨在评估伊匹木单抗联合信迪利单抗新辅助治疗可切除的MSI-H/dMMR结肠癌对比直接根治性手术的有效性和安全性。伊匹木单抗联合信迪利单抗组与信迪利单抗单药组术后病理淋巴结阳性率分别为3.9%与15.9%。伊匹木单抗联合信迪利单抗用于可切除的MSI-H/dMMR结肠癌患者的新辅助治疗的NDA在NMPA优先审评中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4625139_ZH25139_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1589","PP","BK4500","BK4008","CDE","BK4017","IVBIY","BK1161","ALK","BK4585","BK4588","LU2488822045.USD","BK1583","01801","BK4139","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2513695217","title":"【信达生物(01801.HK)：伊匹木单抗注射液联合信迪利单抗用于结肠癌新辅助治疗的新药上市申请获国家药品监督管理局受理并纳入优先审评】信达生物(01801.HK)公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513695217","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513695217?lang=zh_cn&edition=full","pubTime":"2025-02-24 07:37","pubTimestamp":1740353863,"startTime":"0","endTime":"0","summary":"信达生物(01801.HK)公布，伊匹木单抗注射液(抗细胞毒T淋巴细胞相关抗原4(CTLA-4单抗，研发代号：IBI310)联合信迪利单抗用于可切除的微卫星高度不稳定型(MSI-H)或错配修复缺陷型(dMMR)结肠癌患者的新辅助治疗的新药上市申请(NDA)已获中国国家药品监督管理局(NMPA)药品审评中心(CDE)受理并纳入优先审评程序。伊匹木单抗是首个递交NDA的中国研发的CTLA-4单抗，同时，这也是信迪利单抗奠定其肿瘤免疫治疗领先品牌的又一里程碑。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24073748332964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MSI","LU2272731600.USD","LU2065169927.USD","LU1992135472.HKD","LU2328871848.SGD","LU0354030511.USD","BK4588","LU2065171402.SGD","LU2125909916.SGD","LU2272731782.SGD","BK4585","LU2125909759.SGD","LU2506952097.USD","LU2065170008.USD","LU2506951958.HKD","LU2506952170.USD","LU2506951875.HKD","LU2106854487.HKD","IE00B775SV38.USD","LU0823417737.USD","IE00B3S45H60.SGD","LU1974910355.USD","BK4020","LU0823417653.USD","BK1583","01801","BK4017","LU2247934214.USD","LU1992135399.USD","LU2023250504.SGD","CDE","IE0034235188.USD","LU2322448957.HKD","BK1161","LU1969619763.USD","LU1923622291.USD","LU2488822045.USD","LU2272731865.HKD","LU2023250843.SGD","LU1917777945.USD","LU0354030438.USD","LU2065171311.SGD","LU2473716301.USD","LU2322448791.USD","BK1589","LU0950375773.USD"],"gpt_icon":0},{"id":"2513327024","title":"科尔黛伦矿业2024财年实现净利润58.90百万美元，同比增加156.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513327024","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513327024?lang=zh_cn&edition=full","pubTime":"2025-02-23 00:01","pubTimestamp":1740240077,"startTime":"0","endTime":"0","summary":"2月23日，科尔黛伦矿业公布财报，公告显示公司2024财年净利润为58.90百万美元，同比增加156.63%；其中营业收入为10.71亿美元，同比增加32.22%，每股基本收益为0.15美元。从资产负债表来看，科尔黛伦矿业总负债11.78亿美元，其中短期债务42.98百万美元，资产负债比为1.96，流动比率为0.83。机构评级：截至2025年2月23日，当前有8家机构对科尔黛伦矿业目标价做出预测，其中目标均价为8.84美元，其中最低目标价为7.25美元，最高目标价为10.50美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000149a24fcc4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000149a24fcc4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CDE"],"gpt_icon":0},{"id":"2513290181","title":"Roth MKM：维持Coeur Mining(CDE.US)评级，由买入调整至买入评级, 目标价由8.50美元调整至8.25美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513290181","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513290181?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:51","pubTimestamp":1740156681,"startTime":"0","endTime":"0","summary":"Roth MKM：维持Coeur Mining(CDE.US)评级，由买入调整至买入评级, 目标价由8.50美元调整至8.25美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22005148320972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CDE"],"gpt_icon":0},{"id":"1117840012","title":"Coeur Mining 2024年第四季度调整后每股收益为0.18美元，超过预期的0.14美元，销售额为3.05亿美元，不及预期的3.1432亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117840012","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117840012?lang=zh_cn&edition=full","pubTime":"2025-02-20 05:36","pubTimestamp":1740000987,"startTime":"0","endTime":"0","summary":"Coeur Mining报告季度每股收益为0.18美元，比分析师共识预期的0.14美元高出28.57%。公司报告季度销售额为3.05亿美元，比分析师共识预期的3.1432亿美元低了2.96%。这一数据相比去年同期的2.6209亿美元增长了16.37%。以上内容来自Benzinga Earnings专栏，原文如下：Coeur Mining reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.14 by 28.57 percent. This is a 1000 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $305.00 million which missed the analyst consensus estimate of $314.32 million by","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Coeur Mining 2024年第四季度调整后每股收益为0.18美元，超过预期的0.14美元，销售额为3.05亿美元，不及预期的3.1432亿美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE"],"gpt_icon":1},{"id":"2512193650","title":"加拿大蒙特利尔银行：重申Coeur Mining(CDE.US)优于大市评级, 目标价9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193650","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512193650?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:03","pubTimestamp":1739901785,"startTime":"0","endTime":"0","summary":"加拿大蒙特利尔银行：重申Coeur Mining(CDE.US)优于大市评级, 目标价9.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19020348243294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CDE","BMO"],"gpt_icon":0},{"id":"2512634471","title":"多家国产药企布局“流感神药”、最早年内上市，罗氏速福达前景堪忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2512634471","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512634471?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:28","pubTimestamp":1739888924,"startTime":"0","endTime":"0","summary":"蓝鲸新闻2月18日讯 近年来，几乎一到流感季，“流感神药”玛巴洛沙韦（速福达）都会掀起一股购药热潮，零售价格出现大幅上涨。今年1月，流感再度高发，根据蓝鲸财经线下走访发现，不少药店的玛巴洛沙韦库存紧张，有些药店更是定价高至300元/盒，远高于其医保谈判后的医保支付价为222.36元/盒。不过，国产“流感神药”的研发也在加速。据悉，这两款药物均与有“流感神药”之称的玛巴洛沙韦作用机制类似，有望最快于今年年内上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/251125","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["01477","BK4017","CDE","BK1574","BK1191"],"gpt_icon":0},{"id":"2512499189","title":"诺诚健华(688428.SH)：BCL2抑制剂ICP-248联合奥布替尼治疗一线CLL/SLL的注册性Ⅲ期临床试验获CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2512499189","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512499189?lang=zh_cn&edition=full","pubTime":"2025-02-17 19:27","pubTimestamp":1739791662,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)公告，公司于近日获悉，公司自主研发的BCL2抑制剂ICP-248 (Mesutoclax) 联合 BTK 抑制剂奥布替尼治疗一线慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(以下简称“CLL/SLL”)获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展注册性III期临床试验。目前公司已启动该临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1161","09969","BK4017","CDE","BK1583","688428","BK1576","BK1574","BK0239","BK1141"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.coeur.com","stockEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.2456},{"period":"3month","weight":0.0988},{"period":"6month","weight":-0.1108},{"period":"1year","weight":0.7759},{"period":"ytd","weight":0.1084}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":-0.0457},{"period":"3month","weight":-0.0469},{"period":"6month","weight":-0.0077},{"period":"1year","weight":0.0839},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Coeur Mining, Inc.是一家主要的白银生产商，目前其黄金生产也不断加大。该公司在美国，墨西哥，玻利维亚，阿根廷和澳大利亚都有其资产。该公司于2010年8月售出其在智利的Cerro Bayo矿产。Coeur矿业公司于1928年在爱达荷州注册成立。该公司的业务策略是发现，获取，开发和运营低成本金银的业务。该业务将产生长期的现金流，并通过不断的探索提供增长机会，为股东带来卓越和持续的回报。","yearOnYearQuotes":[{"month":1,"riseRate":0.488889,"avgChangeRate":0.023458},{"month":2,"riseRate":0.555556,"avgChangeRate":0.033755},{"month":3,"riseRate":0.511111,"avgChangeRate":0.021987},{"month":4,"riseRate":0.4,"avgChangeRate":-0.002059},{"month":5,"riseRate":0.466667,"avgChangeRate":0.009742},{"month":6,"riseRate":0.355556,"avgChangeRate":-0.011055},{"month":7,"riseRate":0.466667,"avgChangeRate":0.023386},{"month":8,"riseRate":0.577778,"avgChangeRate":0.018315},{"month":9,"riseRate":0.4,"avgChangeRate":0.017014},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.048526},{"month":11,"riseRate":0.511111,"avgChangeRate":0.0047},{"month":12,"riseRate":0.377778,"avgChangeRate":0.012574}],"exchange":"NYSE","name":"科尔黛伦矿业","nameEN":"Coeur Mining"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科尔黛伦矿业(CDE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科尔黛伦矿业(CDE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科尔黛伦矿业,CDE,科尔黛伦矿业股票,科尔黛伦矿业股票老虎,科尔黛伦矿业股票老虎国际,科尔黛伦矿业行情,科尔黛伦矿业股票行情,科尔黛伦矿业股价,科尔黛伦矿业股市,科尔黛伦矿业股票价格,科尔黛伦矿业股票交易,科尔黛伦矿业股票购买,科尔黛伦矿业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科尔黛伦矿业(CDE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科尔黛伦矿业(CDE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}